Highlights {#s1}
==========

1.  What is already known about this topic?

    The relationship between proton pump inhibitors (PPIs) and asthma is controversial. Proton pump inhibitors are the most common acid-suppressive medications of GERD which can contribute to asthma symptoms or has been identified as a potential trigger for asthma. Increasing numbers of studies have suggested PPIs are associated with significant rise of adverse health outcomes.

2.  What does this article add to our knowledge?

    Our data suggest that patients with long-time PPI use have a significantly higher risk of developing asthma when compared with the general population, regardless of gender and age.

3.  How does this study impact current management guidelines?

    The higher risk of developing asthma of patients with long-duration PPI use is identified based on the general population. We recommended H2RA use prior to PPIs in patients who have no underlying peptic ulcers.

Introduction {#s2}
============

Clinically, gastroesophageal reflux disease (GERD) is often reported to be a common cause of chronic cough ([@B25]; [@B23]). GERD can also contribute to asthma symptoms or has been identified as a potential trigger for asthma ([@B13]; [@B36]; [@B20]; [@B11]). The cause may be an aspiration of acid or gastric contents into airways and alveoli, which then leads to stimulation of receptors in the lower respiratory tract or chronic inﬂammation and damage to the alveolar-capillary membrane ([@B37]). GERD and asthma often coexist: GERD has a prevalence ranging from 30 to 90% in persons with asthma compared to an average of 24% in non-asthmatic controls ([@B7]; [@B8]).

GERD treatments include the use of proton pump inhibitors (PPIs), which are the most common acid-suppressive medications ([@B16]) and the first-line antisecretory therapy ([@B39]). PPIs are often used for empiric management of chronic cough with a suspected relationship to GERD ([@B24]); indeed, two placebo-controlled trials have suggested that PPI treatment relieves GERD-related chronic cough ([@B20]). Many studies have been conducted to evaluate and confirm the efficacy of PPI therapy on asthma outcome in patients with asthma with or without GERD. For example, aggressive acid suppressive therapy with omeprazole for 3 months improved asthma symptoms and pulmonary function in 73% of asthmatics with GERD ([@B34]).

PPI is a key component in the treatment of chronic cough due to GERD and an optimum regimen to improve asthma symptoms and pulmonary function in select patients. The aim of this study was to identify the association between PPI use in non-asthma subjects and their subsequent asthma prevalence.

Methods {#s3}
=======

Data Resources {#s3_1}
--------------

This study is a nationwide, population-based retrospective cohort study based on the Taiwan National Health Insurance Research Database (NHIRD) of one million patients between January1, 1999 and December 31, 2013. The NHIRD, established by the Bureau of National Health Insurance (BNHI) and the National Health Research Institutes (NHRI), included health care data that covered more than 99% of the Taiwanese population (approximately 23 million people) (<https://www.nhi.gov.tw/english/Default.aspx>). For patient privacy, the patient identity numbers are encrypted by the NHIRD. The database is a record of all the insurance information, such as medical records, and includes disease diagnosis, drug prescriptions (order date and duration, drug name, dosage, frequency, and administration route), medical procedures, and date of clinic visits and hospitalizations ([@B30]). The diseases in the NHIRD were defined according to the International Statistical Classification of Diseases and Related Health Problems-9th Edition, clinical modification (ICD-9-CM) codes.

This study was approved by the Institutional Review Board (IRB) of Chung Shan Medical University Hospital, Taiwan (CS15134). The IRB waived the need for informed consent for this retrospective study, based on the NHIRD. All protocols were performed in accordance with the relevant guidelines and regulations and were under the surveillance of the IRB of Chung Shan Medical University Hospital.

Study Population {#s3_2}
----------------

The new PPI users were selected from one million random samples from the NHIRD between 2000 and 2012 by searching for use of the PPI drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole for more than 90 days and patient age more than twenty years. The index date was operationalized as the first date of PPI use. The outcome of the analysis was a diagnosis of asthma. The asthma cases were included from the same random samples using the codes ICD-9-CM 493.XX and included admitted inpatients or outpatients with at least two visits to the outpatient department clinics. The asthma-related comorbidities of hypertension patients were identified using the ICD-9-CM codes 401-405, and hyperlipidemia was identified with the ICD-9-CM codes 272.0-272.4. Other selected conditions included GERD (ICD-9-CM codes 530.11 and 530.81), allergic rhinitis (ICD-9-CM codes 472, 473 and 477), atopic dermatitis (ICD-9-CM codes 691), peptic ulcer disease (ICD-9-CM codes 531-534.9), diabetes (ICD-9-CM codes 250), and sleep apnea syndrome (ICD-9-CM codes 327.23, 780.51, 780.52, 780.53, and780.57).

In the treatment cohort, 65,291 new PPI users were enrolled, and 64,331 patient samples were obtained after matching to 128,662 non-PPI users in the control group by age and gender in 1:2 ratios ([**Figure 1**](#f1){ref-type="fig"}). After a follow-up duration of more than ninety days and excluding the asthma cases diagnosed before the index date, 52,389 PPI users in the case group and 113,026 non-PPI patients in the control group were enrolled. Patients who had been diagnosed with asthma prior to the use of PPIs were excluded to ensure that a causal relationship could be analyzed in this study.

![Case selection flow chart of patient selection from one million nationally representative patients in the Taiwan National Health Insurance Research Database PPI, proton pump inhibitor; H2RA, histamine 2 receptor antagonists; NSAIDs, nonsteroidal anti-inflammatory drugs.](fphar-11-00607-g001){#f1}

The PPI case group and the non-PPI control group also were matched by propensity score on a one-to-one ratio for age, gender, comorbidities (*e.g.*, hypertension, hyperlipidemia, GERD, allergic rhinitis, atopic dermatitis, peptic ulcer disease, diabetes, and sleep apnea syndrome), and medications (*e.g.*, histamine 2 receptor antagonists \[H2RA\], nonsteroidal anti-inflammatory drugs \[NSAIDs\], and acetaminophen). Ultimately, 24,077 subjects were included in the PPI group and 24,077 in the non-PPI group.

Data Processing and Statistical Analysis {#s3_3}
----------------------------------------

We used the Chi-square test for categorical variables and t-tests for continuous variables to analyze the differences in the demographic data between the PPI and non-PPI groups. The Kaplan--Meier method was used to estimate the cumulative asthma incidence for the two cohorts in the follow-up period and the log-rank test was used to examine the difference. Multivariate Cox regression models were used to calculate the adjusted hazard ratios (HRs, including the 95% confidence intervals \[CIs\]) of the PPI group for non-PPI group after adjusting for age, gender, hypertension, hyperlipidemia, GERD, allergic rhinitis, peptic ulcer disease, diabetes, sleep apnea syndrome, H2RA, NSAIDs, and acetaminophen. All data analyses were performed using SPSS 18.0 (SPSS Inc., Chicago, IL, USA). A two-tailed P-value of 0.05 was considered statistically significant in this study.

Results {#s4}
=======

The study cohorts consisted of 24,077 matched PPI patients and 24,077 matched non-PPI control subjects. The age and gender distributions were similar in both cohorts ([**Table 1**](#T1){ref-type="table"}). Most subjects were 40--65 years of age (53.8% of PPI and 53.3% of non-PPI). The mean ages of the PPI and non-PPI cohorts were 55.8 ± 15.5 and 56.7 ± 15.1 years, respectively.

###### 

Demographic characteristics, comorbidity, and medication in patients with asthma using or not using proton pump inhibitors (PPIs).

                         Unmatched                   Matched                                                                  
  ---------------------- ------------- ------------- --------- ------------- ------------- ----------- ------ -------- ------ -------
  Age                                                                        0.006\*                          0.168           
   20--40                9,390         17.9          19,774    17.5                        3,818       15.9   3,745    15.6   
   40--65                28,632        54.7          61,485    54.4                        12,959      53.8   12,845   53.3   
   \>=65                 14,367        27.4          31,767    28.1                        7,300       30.3   7,487    31.1   
   Mean ± SD             54.8 ± 15.4   55.1 ± 15.4   0.001\*   55.8 ± 15.5   56.7 ± 15.1   \<0.001\*                          
  Gender                                                                     0.076                                            0.784
   Male                  23,705        45.2          51,670    45.7                        13,135      54.6   13,105   54.4   
   Female                28,684        54.8          61,356    54.3                        10,942      45.4   10,972   45.6   
  Hypertension           15,915        30.4          22,644    20.0          \<0.001\*     7,429       30.9   7,533    31.3   0.306
  Hyperlipidemia         7,270         13.9          8,618     7.6           \<0.001\*     3,171       13.2   3,247    13.5   0.308
  GERD                   5,418         10.3          344       0.3           \<0.001\*     341         1.4    344      1.4    0.908
  Allergic rhinitis      4,439         8.5           4,764     4.2           \<0.001\*     1,740       7.2    1,802    7.5    0.279
  Atopic dermatitis      359           0.7           555       0.5           \<0.001\*     157         0.7    159      0.7    0.910
  Peptic ulcer disease   26,648        50.9          3,333     2.9           \<0.001\*     3,336       13.9   3,333    13.8   0.968
  Diabetes               8,549         16.3          9,774     8.6           \<0.001\*     3,748       15.6   3,798    15.8   0.531
  Sleep apnea syndrome   3,209         6.1           2,983     2.6           \<0.001\*     1,274       5.3    1,289    5.4    0.761
  H2RA                   19,240        36.7          6,228     5.5           \<0.001\*     5,786       24.0   5,758    23.9   0.765
  NSAIDs                 25,288        48.3          33,473    29.6          \<0.001\*     10,818      44.9   11,003   45.7   0.090
  Acetaminophen          23,402        44.7          23,927    21.2          \<0.001\*     9,476       39.4   9,625    40.0   0.165

\*p \< 0.01.

PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease; H2RA, histamine 2 receptor antagonists; NSAIDs, nonsteroidal anti-inflammatory drugs.

The comorbidities, including allergic rhinitis, atopic dermatitis, GERD, peptic ulcer disease, hypertension, hyperlipidemia, diabetes, sleep apnea syndrome, and use of H2RA, NSAIDs, and acetaminophen, were significantly different between the unmatched PPI patients and the non-PPI controls (*p-values \<0.001*), but no difference was observed between the matched PPI and non-PPI groups. The average follow-up period was 5.7 ± 3.4 years (137,582 person-years) for the PPI cohort and 6.9 ± 3.5 years (165,323 person-years) for the non-PPI cohort. Kaplan--Meier analysis showed that the cumulative probability of developing asthma by the end of the 14-year follow-up period was higher for the PPI cohort than for the non-PPI cohort (log-rank test, *p \< 0.001*; [**Figure 2**](#f2){ref-type="fig"}).

![Cumulative incidence of asthma in patients with and without proton pump inhibition (PPI) use.](fphar-11-00607-g002){#f2}

[**Table 2**](#T2){ref-type="table"} shows a total of 3,216 asthma events (1,823 for the PPI cohort and 1,393 for the non-PPI cohort). The incidence was 1.70-fold higher (95% CI, 1.59--1.83) in the PPI cohort than in the non-PPI cohort (13.3 *vs.* 8.4 per 1,000 person-years), with an adjusted HR of 1.76 (95% CI, 1.64--1.88) after controlling for age, gender, comorbidities, and medications. The incidence of asthma decreased with age in both cohorts (*p =0.019*), but the age-specific adjusted HRs for the PPI cohort, when compared with the non-PPI cohort, were statistically significant for all age groups. Among the analysis of the listed comorbidities, we found that the asthma prevalence was higher for patients without peptic ulcer disease in the PPI cohort (adjusted HR of 1.95; 95% CI, 1.80--2.11) but did not differ in patients with peptic ulcer disease (adjusted HR of 1.14; 95% CI, 0.97--1.34). Patients not using H2RA before PPIs had a higher incidence of asthma (adjusted HR of 1.81; 95% CI, 1.66--1.96) than in those cases who had used H2RA (adjusted HR of 1.58; 95% CI, 1.38--1.79). If the patients were not exposed to asthma-related medications (NSAIDs and acetaminophen), the asthma risks due to PPI use were also higher (adjusted HR of 1.93; 95% CI, 1.73--2.15 in the NSAIDs cohort and 1.88; 95% CI, 1.70--2.08 in the acetaminophen cohort).

###### 

Incidence of asthma and the Cox proportional hazard model estimated proton pump inhibitor (PPI) cohort to non-PPI cohort hazard ratio.

                         PPI     Non-PPI                                                        
  ---------------------- ------- --------- ------ ------- --------- ------ -------------------- ----------------------------
  Total                  1,823   137,582   13.3   1,393   165,323   8.4    1.70 (1.59--1.83)    1.76 (1.64--1.88)
  Age                                                                                           
   20--40                196     23,859    8.2    113     27,634    4.1    2.21 (1.75--2.79)    2.22 (1.76--2.80)
   40--65                891     77,631    11.5   643     91,818    7.0    1.81 (1.63--2.00)    1.83 (1.66--2.03)
   \>=65                 736     36,091    20.4   637     45,870    13.9   1.56 (1.41--1.74)    1.60 (1.44--1.78)
                                                                                                p for interaction = 0.019
  Gender                                                                                        
   Male                  894     75,156    11.9   721     90,282    8.0    1.61 (1.46--1.78)    1.65 (1.50--1.83)
   Female                929     62,426    14.9   672     75,041    9.0    1.80 (1.63--1.99)    1.86 (1.69--2.06)
                                                                                                p for interaction= 0.127
  Hypertension                                                                                  
   No                    1,187   100,312   11.8   839     119,430   7.0    1.86 (1.70--2.03)    1.90 (1.74--2.08)
   Yes                   636     37,270    17.1   554     45,893    12.1   1.50 (1.34--1.68)    1.55 (1.38--1.74)
                                                                                                p for interaction = 0.009
  Hyperlipidemia                                                                                
   No                    1,590   121,675   13.1   1,206   146,560   8.2    1.73 (1.60--1.86)    1.78 (1.65--1.92)
   Yes                   233     15,908    14.6   187     18,763    10.0   1.54 (1.27--1.87)    1.60 (1.32--1.94)
                                                                                                p for interaction = 0.354
  GERD                                                                                          
   No                    1,803   136,289   13.2   1,380   163,997   8.4    1.70 (1.59--1.83)    1.76 (1.64--1.89)
   Yes                   20      1,293     15.5   13      1,326     9.8    1.57 (0.78--3.16)    1.57 (0.77--3.20)
                                                                                                p for interaction = 0.786
  Allergic rhinitis                                                                             
   No                    1,652   128,132   12.9   1,236   153,854   8.0    1.74 (1.62--1.87)    1.80 (1.67--1.94)
   Yes                   171     9,450     18.1   157     11,469    13.7   1.41 (1.14--1.75)    1.44 (1.15--1.79)
                                                                                                p for interaction = 0.065
  Atopic dermatitis                                                                             
   No                    1,806   136,762   13.2   1,380   164,317   8.4    1.70 (1.59--1.83)    1.80 (1.68--1.93)
   Yes                   17      820       20.7   13      1,006     12.9   1.70 (0.82--3.50)    1.76 (0.84--3.69)
                                                                                                p for interaction = 0.908
  Peptic ulcer disease                                                                          
   No                    1,521   117,586   12.9   1,089   143,531   7.6    1.87 (1.73--2.02)    1.95 (1.80--2.11)
   Yes                   302     19,996    15.1   304     21,792    13.9   1.11 (0.95--1.30)    1.14 (0.97--1.34)
                                                                                                p for interaction \< 0.001
  Diabetes                                                                                      
   No                    1,547   120,310   12.9   1,163   142,852   8.1    1.72 (1.59--1.85)    1.76 (1.63--1.90)
   Yes                   276     17,272    16.0   230     22,471    10.2   1.66 (1.39--1.97)    1.72 (1.44--2.05)
                                                                                                p for interaction = 0.943
  Sleep apnea syndrome                                                                          
   No                    1,722   131,137   13.1   1,298   157,665   8.2    1.73 (1.61--1.86)    1.78 (1.66--1.92)
   Yes                   101     6,445     15.7   95      7,658     12.4   1.32 (0.997--1.75)   1.33 (1.002--1.76)
                                                                                                p for interaction = 0.074
  H2RA                                                                                          
   No                    1,292   97,235    13.3   983     119,937   8.2    1.75 (1.61--1.90)    1.81 (1.66--1.96)
   Yes                   531     40,347    13.2   410     45,386    9.0    1.56 (1.37--1.77)    1.58 (1.38--1.79)
                                                                                                p for interaction = 0.029
  NSAIDs                                                                                        
   No                    803     61,456    13.1   560     75,846    7.4    1.84 (1.65--2.05)    1.93 (1.73--2.15)
   Yes                   1,020   76,126    13.4   833     89,477    9.3    1.58 (1.44--1.73)    1.61 (1.47--1.76)
                                                                                                p for interaction \< 0.001
  Acetaminophen                                                                                 
   No                    931     72,357    12.9   626     85,788    7.3    1.82 (1.65--2.02)    1.88 (1.70--2.08)
   Yes                   892     65,225    13.7   767     79,535    9.6    1.58 (1.44--1.74)    1.64 (1.49--1.81)
                                                                                                p for interaction = 0.001

PY, Person-years; Rate, 1/1,000 Person-Years; PPI, proton pump inhibitor; GERD, gastroesophageal reflux disease; H2RA, histamine 2 receptor antagonists; NSAIDs, nonsteroidal anti-inflammatory drugs.

[**Table 3**](#T3){ref-type="table"} shows the results of the Cox proportional hazard model estimated PPI hazard ratio among the different PPI types. Esomeprazole, lansoprazole, omeprazole, and pantoprazole were significantly related to asthma risk, but rabeprazole was not (adjusted HR of 1.04; 95% CI, 0.94--1.15).

###### 

Cox proportional hazard model estimated proton pump inhibitor (PPI) hazard ratio among different PPI types.

                 N        No. of asthma event   Crude HR   95% C.I.     Adjusted HR^†^   95% C.I.
  -------------- -------- --------------------- ---------- ------------ ---------------- ------------
  Esomeprazole   12,807   1,071                 1.27\*     1.17--1.38   1.26\*           1.15--1.37
  Lansoprazole   13,842   1,187                 1.18\*     1.08--1.28   1.23\*           1.13--1.34
  Omeprazole     10,530   1,054                 1.36\*     1.25--1.49   1.38\*           1.26--1.50
  Pantoprazole   10,131   841                   1.15\*     1.05--1.26   1.13\*           1.04--1.24
  Rabeprazole    5,705    448                   1.01       0.91--1.12   1.04             0.94--1.15

^†^Adjusted for age, gender, hypertension, hyperlipidemia, GERD, allergic rhinitis, atopic dermatitis, peptic ulcer disease, diabetes, sleep apnea syndrome, H2RA, NSAIDs, and acetaminophen.; \*p \< 0.01.

Discussion {#s5}
==========

To our knowledge, this is the first study to evaluate the relationship between PPI use and the subsequent risk of asthma. We identified a significant risk of asthma among patients using PPIs when compared to the non-PPI population after matching by propensity score and adjusting for age, gender, comorbidities, and asthma medications. The incidence of asthma was higher in patients not using H2RA before PPIs than in those cases who had used H2RA. Patients not exposed to asthma-related medications (NSAIDs and acetaminophen) also had a higher asthma risk due to PPIs (adjusted HR of 1.93 in the NSAIDs cohort and 1.88 in the acetaminophen cohort).

Many studies have proved that some medications, like aspirin, NSAIDs, and acetaminophen, may be related to the risk of asthma. The use of acetaminophen may represent an important risk factor for the development and/or maintenance of asthma in adolescent children ([@B3]). For example, paracetamol exposure in pregnancy and early infancy has been considered to have an association with the subsequent development of childhood asthma (age ≥ 5 years) ([@B10]). A previous retrospective cohort study of the Taiwan NHIRD indicated that short-term aspirin, ibuprofen, and diclofenac use was probably correlated with asthma exacerbation in asthmatic children ([@B32]). However, none of these studies mentioned any possible association of acid-suppressive therapy and asthma risk. The fully adjusted Cox regression model presented in our study for competing risk analysis (*i.e.*, age, gender, allergic rhinitis, atopic dermatitis, GERD, peptic ulcer disease, hypertension, hyperlipidemia, diabetes, sleep apnea syndrome, and use of H2RA, NSAIDs, and acetaminophen) suggests that PPIs may play an independent role in the development of asthma.

PPIs inhibit the H^+^-K^+^-ATPase, which is the final step of gastric acid secretion by parietal cells. Since the 1980s, when the first generation of PPIs was made available, PPIs have become the most commonly used medications for acid suppression ([@B16]). PPIs are the first-line anti-secretory therapy in the treatment of peptic ulcer disease and are indicated as a treatment for GERD, including erosive esophagitis, and as maintenance therapy in patients with severe erosive esophagitis or Barrett's esophagus ([@B39]). PPIs are also effective in preventing NSAID-induced gastroduodenal toxicity and in healing gastroduodenal ulcers associated with NSAIDs when NSAIDS cannot be discontinued ([@B1]). In the COGENT trial, prophylactic use of a PPI reduced the rate of upper gastrointestinal bleeding among patients receiving aspirin and clopidogrel ([@B4]).

In recent years, increasing numbers of studies have suggested an association between PPIs and an increased risk of adverse health outcomes. Some studies have shown that PPIs are associated with a significant rise in acute interstitial nephritis ([@B6]), chronic kidney disease (CKD) ([@B28]), kidney disease progression, and end-stage renal disease ([@B40]). A large prospective observational German cohort study showed that patients receiving PPIs had a higher risk of incident dementia ([@B17]). PPI use has been associated with an increased risk of incident and recurrent *Clostridium difficile* infections ([@B26]), community-acquired pneumonia ([@B14]), and hospital-associated pneumonia ([@B21]). A relationship between cardiovascular events and PPI use has also been mentioned ([@B35]). A longitudinal observational cohort study of United States veterans also found an increased risk of death among users of PPIs ([@B40]). Our study found that PPI use is an independent risk for asthma.

Aggressive acid suppressive therapy with PPIs has been recommended to improve asthma outcomes in asthmatics with GERD. A study of 30 nonsmoking adult asthmatics with GERD found that a 3-month regimen of acid suppressive therapy with omeprazole improved asthma symptoms and pulmonary function in 73% of the subjects ([@B19]). Two placebo-controlled trials that investigated the efficacy of PPI on GERD-related chronic cough indicated that PPI treatment relieves GERD-related chronic cough but recommended using a double-standard dose of the PPI for a minimum of 2 to 3 months ([@B20]). However, a parallel-group, double-blind trial of 412 participants with asthma inadequately controlled by inhaled corticosteroids and with minimal or no symptoms of GERD showed no improvement in asthma outcomes by a treatment with 40 mg esomeprazole twice a day; these findings indicated that asymptomatic GERD might not be a possible cause of poorly controlled asthma ([@B33]).

A review study identified 13 publications from 1989 to 2012 related to treatment of asymptomatic GERD in school-age children with asthma poorly controlled by inhaled corticosteroids. The FDA-approved doses of PPIs did not improve their asthma outcomes ([@B5]); consequently, the authors commented that GERD and asthma may be associated by chance alone, because GERD is highly prevalent in the general population ([@B12]).

PPIs provide a stronger acid suppression when compared to H2RA, so they result in a faster control of peptic ulcer disease symptoms and higher ulcer healing rates ([@B38]). A meta-analysis that enrolled fourteen trials and a total of 1,720 patients concluded that PPIs were more effective than H2RA at reducing clinically important and overt upper gastrointestinal bleeding. No differences were noted between PPIs and H2RA in the risk of nosocomial pneumonia, ICU mortality, or ICU length of stay ([@B2]). However, a decision-analytic model aimed at determining the cost effectiveness of stress ulcer prophylaxis with H2RA versus PPIs in critically ill and mechanically ventilated adults from a health care institutional perspective concluded that providing stress ulcer prophylaxis with H2RA therapy may reduce costs, increase survival, and avoid complications when compared with PPI therapy ([@B18]).

A recent multicenter retrospective study examined the effect of preventing clinically important GI bleeding (CIGIB) with prophylactic PPIs or H2RA among critically ill adults with at least one stress ulcer risk factor in ICU care in US nonfederal hospitals. They found the hazard ratio for CIGIB was two times greater for PPIs patients than for H2RA patients (adjusted HR 1.82 \[95% CI, 1.19--2.78\]) ([@B31]). H2RA administration has been associated with many rare side effects (cardiac arrhythmia; cardiac arrest occurring with rapid infusion ([@B22]; [@B29]); increases in serum creatinine observed with cimetidine; immune-mediated interstitial nephritis; both cholestatic and hepatocellular injury ([@B15]); CNS side effects including confusion, restlessness, somnolence, agitation, headaches, dizziness, and hallucinations and seizures with prolonged therapy ([@B9]); and B12 deficiency with long-term H2RA use ([@B27]); however, many of these adverse effects are rapidly reversible or resolve after withdrawal of the drug ([@B15]). In our study, we found a lower PPI-related asthma risk if the patients used the H2RA first, before PPIs use.

Some past studies have found an association between GERD and asthma; however, no causal link between GERD and asthma was evident in our study. Conversely, we found that PPIs, rather than GERD, influence the subsequent occurrence of asthma. Our results showed that most PPIs were associated with asthma risk; the exception was rabeprazole. Our smaller patient sample size is a likely explanation, but further study could be considered to evaluate this difference.

Some limitations of this study should be considered. First, we could not establish a causal relationship between PPIs and asthma risk based on this retrospective cohort study. A prospective double blind study would be more convincing. Second, we found a higher incidence of asthma for the patients without peptic ulcer or exposure to asthma-related medications (NSAIDs and acetaminophen) in the PPI group than in the non-PPI group. A well-designed randomized control trial is necessary to confirm the higher asthma risk of PPIs, but PPIs are more popular regimens clinically due to their strong antacid effects and relatively low cost. Third, we noticed that rabeprazole did not increase the asthma risk, in contrast to the other PPIs (esomeprazole, lansoprazole, omeprazole, and pantoprazole). We are unable to explain this difference, but it might reflect the lower use of rabeprazole in our study population or, indeed, a pharmacological difference.

Conclusions {#s6}
===========

Our data suggest that patients with long-time PPI use have a significantly higher risk of developing asthma when compared with the general population, regardless of gender and age. We recommended H2RA use prior to PPIs in patients who have no underlying peptic ulcers. The pathophysiological association between PPIs and asthma needs further investigation.
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